Fondaparinux sodium Evumed
Opinion
fondaparinux sodium
MedicineHumanOpinion
Latvian is available via eTranslation, the European Commission's machine translation service.
Translate to Latvian | Important information about machine translation
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fondaparinux sodium Evumed, intended for the prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery or immobilised due to acute illness, and for the treatment of unstable angina and myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism.
The applicant for this medicinal product is Evumed Limited.
Fondaparinux sodium Evumed will be available as 2.5 mg, 5 mg, 7.5 mg and 10 mg solution for injection in a pre-filled syringe. The active substance of Fondaparinux sodium Evumed is fondaparinux sodium, an antithrombotic agent (ATC code: B01AX05) which works by blocking Factor Xa, a protein involved in the blood-clotting process, thereby reducing the formation of blood clots.
Fondaparinux sodium Evumed is a generic of Arixtra, which has been authorised in the EU since 21 March 2002. Studies have demonstrated the satisfactory quality of Fondaparinux sodium Evumed. Since Fondaparinux sodium Evumed is administered parenterally and is 100% bioavailable, a bioequivalence study versus the reference product Arixtra was not required.
The full indication for Fondaparinux sodium Evumed 2.5 mg/ 0.5 ml solution for injection is:
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1).
Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management (percutaneous coronary interventions - PCI) is not indicated (see sections 4.4 and 5.1).
Treatment of ST segment elevation myocardial infarction (STEMI) in adults who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (see sections 4.4 and 5.1).
The full indication for Fondaparinux sodium Evumed 5 mg/ 0.4 ml, 7.5 mg/ 0.6 ml, and 10 mg/ 0.8 ml solution for injection is:
Treatment of adults with acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.
Generic
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.